Efficacy and safety of linagliptin as add‐on therapy to insulin in Chinese patients with type 2 diabetes mellitus: A randomized, double‐blind, placebo‐controlled trial-Reference-Cited by-同舟云学术

Efficacy and safety of linagliptin as add‐on therapy to insulin in Chinese patients with type 2 diabetes mellitus: A randomized, double‐blind, placebo‐controlled trial

Published:2020-11-06 Issue:2 Volume:23 Page:642-647
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Yang Wenying¹^ORCID,Xu Xiangjin²,Lei Tao³,Ma Jianhua⁴,Li Ling⁵,Shen Jie⁶,Ye Binqi⁶,Zhu Sandy⁶,Meinicke Thomas⁷

Affiliation:

1. China‐Japan Friendship Hospital Beijing People's Republic of China

2. The 900th Hospital of Joint Logistic Support Force, PLA Fujian People's Republic of China

3. Putuo Hospital Shanghai University of Traditional Chinese Medicine Shanghai People's Republic of China

4. Nanjing First Hospital Nanjing Medical University Nanjing People's Republic of China

5. Shengjing Hospital of China Medical University Endocrinology Liaoning People's Republic of China

6. Boehringer Ingelheim (China) Investment Co. Ltd Shanghai People's Republic of China

7. Boehringer Ingelheim International GmbH Ingelheim Germany

Funder

Boehringer Ingelheim

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.14231

Reference19 articles.

1. Insulin resistance and β-cell dysfunction as therapeutic targets in type 2 diabetes

2. Observational Registry of Basal Insulin Treatment (ORBIT) in patients with type 2 diabetes uncontrolled with oral antihyperglycaemic drugs: Real-life use of basal insulin in China

3. A review of gliptins in 2011

4. Efficacy and safety of the addition of a dipeptidyl peptidase-4 inhibitor to insulin therapy in patients with type 2 diabetes: A systematic review and meta-analysis

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pancreatitis and Pancreatic Cancer Risk Among Patients With Type 2 Diabetes Receiving Dipeptidyl Peptidase 4 Inhibitors: An Updated Meta-Analysis of Randomized Controlled Trials;Clinical Therapeutics;2024-08

2. Individual dipeptidyl peptidase‐4 inhibitors and acute kidney injury in patients with type 2 diabetes: A systematic review and network meta‐analysis;Basic & Clinical Pharmacology & Toxicology;2024-05-02

3. Safety of Linagliptin in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis of Randomized Clinical Trials;Therapeutic Innovation & Regulatory Science;2024-04-18

4. A Comprehensive Review on Weight Loss Associated with Anti-Diabetic Medications;Life;2023-04-14

5. Dipeptidyl peptidase-4 inhibitors and gallbladder or biliary disease in type 2 diabetes: systematic review and pairwise and network meta-analysis of randomised controlled trials;BMJ;2022-06-28